Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving…
BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinsons disease
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at…
NYSE Content Advisory: Pre-Market update + S&P 500 closes above 6,700 for first time
NEW YORK, Oct. 2, 2025 /PRNewswire/ -- The New York Stock Exchange…
Delska’s New 10MW Data Center in Latvia Achieves Tier III Design Certification
RIGA, Latvia, Aug. 19, 2025 /PRNewswire/ -- Northern European data center operator Delska's upcoming…
Cango Inc. Announces Completion of Secondary Acquisition and Appointment of New Leadership Team
HONG KONG, July 23, 2025 /PRNewswire/ -- Cango Inc. (NYSE: CANG) today…
Jyong Biotech Ltd. Announces Closing of $20 Million Initial Public Offering
New Taipei City, Taiwan, June 18, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech…
Energize Capital raises $430 million to capitalize and scale digitally-enabled climate solutions
Backed by leading institutional Limited Partners, Ventures Fund III underscores the need…
Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition…
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde regimen in metastatic pancreatic adenocarcinoma
Phase III NAPOLI 3 trial is the largest and has the longest…